# A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

> **NCT05615363** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 157 (actual)

## Conditions studied

- Cardiac Edema (CHF)

## Interventions

- **DRUG:** OPC 131461 10mg group
- **DRUG:** OPC 131461 5mg group
- **DRUG:** OPC 131461 2mg group
- **DRUG:** OPC 131461 1mg group
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05615363
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-10
- **Primary completion:** 2024-10-21
- **Final completion:** 2024-10-21
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05615363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05615363, "A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05615363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*